KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arbutus Biopharma (ABUS) Cash & Equivalents (2016 - 2025)

Arbutus Biopharma's Cash & Equivalents history spans 16 years, with the latest figure at $22.4 million for Q3 2025.

  • For Q3 2025, Cash & Equivalents fell 29.64% year-over-year to $22.4 million; the TTM value through Sep 2025 reached $22.4 million, down 29.64%, while the annual FY2024 figure was $36.3 million, 38.22% up from the prior year.
  • Cash & Equivalents for Q3 2025 was $22.4 million at Arbutus Biopharma, down from $37.4 million in the prior quarter.
  • Across five years, Cash & Equivalents topped out at $109.3 million in Q4 2021 and bottomed at $17.5 million in Q3 2023.
  • The 5-year median for Cash & Equivalents is $34.1 million (2024), against an average of $46.3 million.
  • The largest annual shift saw Cash & Equivalents soared 200.65% in 2021 before it plummeted 71.84% in 2022.
  • A 5-year view of Cash & Equivalents shows it stood at $109.3 million in 2021, then tumbled by 71.84% to $30.8 million in 2022, then decreased by 14.59% to $26.3 million in 2023, then skyrocketed by 38.22% to $36.3 million in 2024, then plummeted by 38.32% to $22.4 million in 2025.
  • Per Business Quant, the three most recent readings for ABUS's Cash & Equivalents are $22.4 million (Q3 2025), $37.4 million (Q2 2025), and $26.4 million (Q1 2025).